Arthneeti
RB

Rossari Biotech Ltd

Q3 FY26Chemicals & Petrochemicals

Rossari Biotech Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹502
Market cap₹2.8K Cr
P/E18.5
Updated23 Aug 2026
Read5 min read

The short version

Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Earnings growth expected to continue, supported by steady volume growth across business segments.

From Rossari Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26.
  • Domestic demand, especially in textiles, remains soft but export markets like Southeast Asia, MENA, Middle East, and Turkey show promise.
  • Animal Health and Nutrition (AHN) business demonstrated strong growth; expected to maintain average growth with new premix plant coming onstream.
  • Ramp-up of new capacities at Dahej and Unitop to continue, with optimal utilization targeted by FY27, supporting volume growth.
  • New product development and market expansion prioritized, including setting up a manufacturing facility in KSA to enhance supply chain and export reach.
  • Premix plant for AHN anticipated to contribute volumes from Q4 FY26 onwards and next year.
  • Overall focus on driving sales through key accounts, geographic expansion, and new product introductions for sustainable growth.

Profitability & Margins

See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26.
  • Non-EO based capacities for Unitop, Tristar, and Rossari are planned for the next year, phased for Q3 and Q4 FY26.
  • The Saudi Arabia greenfield specialty chemicals manufacturing facility has received in-principle Board approval; initial equity infusion of $8 million approved for evaluation and groundwork, with the total capex to be determined post-assessment and formal Board approval.
  • Most capacity enhancement CAPEX for FY26 largely capitalized (~Rs. 200 crore group-wide); future CAPEX over next 2-3 years will focus on new product development, piloting, and R&D rather than capacity expansion.
  • The company plans prudent funding of CAPEX through a mix of internal accruals, debt, and exploring regional incentives for KSA project.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Rossari Biotech Limited. However, some relevant points related to demand and order outlook include: - Exports have been growing strongly and contributed about 30% of turnover in the 9 months ended FY26. - Domestic demand, especially in textiles, has been soft but showed some signs of recovery in Q3 FY26. - The company is adding customers in new geographies like Turkey, Uzbekistan, Morocco, Southeast Asia, and others, indicating an expanding order pipeline. - Discussions and in-principle approvals for a new greenfield manufacturing facility in Saudi Arabia are underway, aimed at strategically catering to regional and export demand. - Ramp-up of new capacities at Dahej and Unitop is expected to progressively contribute to order fulfillment over the next 2 years. - The Animal Health and Nutrition (AHN) segment saw strong growth and new market additions. - Overall, order inflows are supported by diversification and export market expansion, with expectations of better demand outlook in Q4 and beyond.

Rossari Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹685 Cr, net profit ₹46 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Rossari Biotech Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Clean Science (Q3 FY26)

    Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China. Key concall takeaways from Clean…

  • Aether Industri. (Q3 FY26)

    The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter. Key concall…

  • Kesar Petroproducts Ltd (Q3 FY26)

    Export markets constitute about 40% of sales, served through 7-8 distributors across geographies. Key concall takeaways from Kesar Petroprod.'s Q3 FY26…

  • Tata Chemicals Ltd (Q3 FY26)

    Indian salt capacity expansion of 210 KT per annum with INR 515 crore investment is underway to meet growing demand. Key concall takeaways from Tata…

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Rossari Biotech Ltd Q3 FY26 results?

Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Earnings growth expected to continue, supported by steady volume growth across business segments.

What is Rossari Biotech Ltd share price analysis?

Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech Ltd planning capital expenditure?

Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26. - Non-EO based capacities for Unitop, Tristar, and Rossari are planned for the next year, phased for Q3 and Q4 FY26. - The Saudi Arabia greenfield specialty chemicals manufacturing facility has received in-principle Board approval; initial equity infusion of $8 million approved for evaluation and groundwork, with the total capex to be determined post-assessment and formal Board approval. - Most capacity enhancement CAPEX for FY26 largely capitalized (~Rs.

Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.